Femasys Gets FDA OK of IDE for Trial of Permanent Birth Control

Femasys, a biomedical company that develops in-office technologies for reproductive health, receives FDA approval of an Investigational Device Exemption for the trial of FemBloc permanent birth control.

• FemBloc is intended to be a safer option for women by eliminating the need for anesthesia, incisions, and permanent implants

To view the source of this information, click here

To contact the reporter on this story:
Lara Sanli in New York at lsanli@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission.